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Highlights
• Fifty-six studies were included in a systematic literature review.
• PICCs were compared to CICCs and PIVCs for short/intermediate-term use in Europe.
• Several efficacy and safety benefits were shown with PICCs.
• Limited evidence showed higher costs with PICCs.
Abstract
Aims: The aim of this systematic review is to examine the efficacy, safety, and costs associated with the short/
intermediate-term use of peripherally inserted central catheters (PICCs) in comparison with centrally inserted 
central catheters (CICCs) and peripheral intravenous catheters (PIVCs) among adults in Europe.
Methods: Medline, EMBASE, Cochrane, and EconLit databases were searched for records dating from January 
2000 to March 2017. Full-text versions of potentially relevant records were assessed according to prespecified 
inclusion and exclusion criteria.
Results: Of 457 identified records, 56 studies were included in the review. Data ranges for efficacy outcomes 
across studies did not suggest any clear advantages or disadvantages between PICCs and CICCs or PIVCs. 
However, individual studies reported statistically significant improvements in patient satisfaction with PICCs 
versus both comparators (P < 0.001) and fewer venipunctures for successful insertion compared with PIVCs (P 
< 0.01). Across studies, rates of removal due to complications were 3.5% to 48% with PICCs compared to 67% 
to 81.2% with PIVCs and 26% to 78% with CICCs. The proportion of patients reporting catheter migration/
dislocation was 0% to 7.7% with PICCs compared to 9.6% to 15% with CICCs, whereas the rate of venous 
thrombosis was 0% to 27.2% versus 0% to 9.6%, respectively, with individual studies reporting significant 
differences (P ≤ 0.01). Limited evidence showed higher costs with PICCs than with CICCs or PIVCs, but not all 
relevant costs were included in the analyses.
Conclusions: This review showed that PICCs offer several advantages compared to CICCs and PIVCs, including 
greater patient satisfaction, fewer complications leading to removal, and less catheter migration/dislocation, 
despite a moderately higher rate of venous thrombosis.
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Introduction
Reliable and easy venous access is essential for the safe and effective care of hospitalized patients. Venous ac-cess devices (VADs) are catheters that consist of a hub 
to provide access to connectors, a hollow tube divided into 
one or many sections (lumens), and a tip terminating within 
a peripheral or central blood vessel.1 VADs can be classified 
as central venous access devices (CVADs), peripheral intrave-
nous catheters (e.g., midlines or peripheral intravenous cathe-
ters [PIVCs]), or implanted ports, based on the site of entry and 
location of the catheter tip.1
CVADs allow for central access, with tip termination in the 
lower portion of the superior vena cava at the cavoatrial junc-
tion.1 Centrally inserted central catheters (CICCs) are CVADs 
that enter directly into veins of the neck or chest. Peripher-
ally inserted central catheters (PICCs) are CVADs that enter 
through peripheral veins of the upper arm but terminate in the 
proximity of the cavoatrial junction.1
PICCs are indicated for both short/intermediate- and long-
term access to the central venous system.2,3 They are used for 
intravenous (IV) therapy (e.g., antibiotics, total parenteral nu-
trition, and chemotherapy), fluid delivery, power injection of 
contrast media, central venous pressure monitoring, and blood 
sampling.4–6 Although PICCs are recognized in Europe as ef-
fective devices for the delivery of long-term treatments of 6 
months or more, there is a lack of consensus regarding their 
utility and advantages over CICCs and PIVCs in the short/in-
termediate term.6,7
Aims
The aim of this systematic review is to examine the efficacy, 
safety, and costs associated with the short/intermediate-term 
(<6 months) use of PICCs among adults in Europe. The two 
main questions to be answered were as follows: (1) What is 
the extent of the available literature on short/intermediate-term 
PICC use among adults in Europe? and (2) What conclusions 
can be drawn from data in the literature about the efficacy, safe-
ty, and costs of short/intermediate-term PICC use among adults 
in Europe compared to CICCs and PIVCs?
Methods
Data Sources
The following electronic databases of the medical literature, 
scientific conference websites, and health agency/organization 
websites, were searched to identify relevant articles published 
from January 1, 2000, to March 30, 2017:
• Medline via PubMed
• EMBASE
• Cochrane Database of Systematic Reviews
• Cochrane Health Technology Assessment (HTA) Data-
base
• Centre for Reviews and Dissemination (CRD)
• EconLit Database
• Conference abstracts from the last 2 years: NIVAS Cen-
tral Venous Access Devices Symposium, French Society 
of Anesthesiology and Intensive Care, UK Infection Pre-
vention Society, Vascular Access Society, Italian Gli Ac-
cessi Venosi Centrali a Lungo Termine (Long-Term Cen-
tral Venous Accesses), and European Society of Intensive 
Care Medicine.
Search Strategy
An initial screen of identified titles/abstracts and other ma-
terials from the gray literature was performed to collate a pool 
of potentially relevant studies. Full-text versions of potentially 
relevant records were then assessed according to the inclusion 
and exclusion criteria to determine eligibility for the review. 
All studies that met the set criteria were thoroughly reviewed 
and assessed for methodologic quality. Exclusion reasons were 
documented for all records screened in full text (see Figure).
The reference lists from the publications selected for inclu-
sion and other systematic reviews and meta-analyses pertinent 
to the topic were screened for other potentially eligible articles.
The following steps were followed for the identification of 
studies:
1. The search strategy across all databases was performed 
by one reviewer.
2. Titles and abstracts of studies identified from the searches 
were screened by one reviewer based on the inclusion/
exclusion criteria (level 1 screening).
3. A sample of 20% of the level 1 screening was conducted 
by a second reviewer to ensure that inclusion/exclusion 
criteria were well understood and that both reviewers 
were obtaining the same results. Any discrepancies were 
discussed until a resolution was found.
4. Full texts of studies accepted at level 1 were further re-
viewed by 2 analysts at level 2. If there was any uncer-
tainty on the study relevance, a third reviewer assessed 
the full text, and the issue was resolved by consensus. All 
reasons for exclusion were documented via the PRISMA 
(Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) diagram.8
Study Selection Criteria
The review questions were addressed in accordance with 
the PICOS scheme (population, intervention, comparators, 
outcomes, and study design) (Table 1) and the specified inclu-
sion/exclusion criteria.9 Studies reporting on efficacy, safety, 
or costs of short/intermediate-term use of PICCs for nonche-
motherapy applications in Europe were included in the review.
Studies with the following were not eligible for inclusion:
• Publication date not within the specified range (January 
1, 2000, to March 30, 2017)
• Patients younger than 18 years
• Relevant outcomes not reported
• Previous deep vein thrombosis (DVT) or known clotting 
disorder
• Improper use of PICCs
• Chemotherapy-related rationale for utilization of the 
PICC (to exclude patients utilizing PICCs for longer-term 
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Table 1. PICOS Framework
Population • Adults (≥18 years) who received PICCs in the short/intermediate term (<6 months) in Europe, including 28 countries 
in European Union, plus Norway and Switzerland
Intervention • Short/intermediate-term (<6 months) use of PICCs, for nonchemotherapy
Comparators • PIVCs
• CICCs, including tunneled and nontunneled catheters
Outcomes • Efficacy
 C Patient comfort and satisfaction
 C Pain during insertion
 C Overall number of catheter days
 C Mean catheter dwell time
 C Placement complications
• Safety
 C Complications leading to catheter removal
 C Accidental catheter removal
 C Catheter blockage/occlusion
 C Catheter migration
 C Catheter fracture
 C Mechanical failure
 C Thrombosis/deep vein thrombosis (DVT)
 C Inflammation
 C Skin reactions
 C Infections
 C Central line–associated bloodstream infection (CLABSI)
 C Bleeding complications
• Costs
 C Resource utilization
 C Inpatient costs
 C Outpatient costs
 C Nonmedical costs
Study design • Randomized controlled trials, nonrandomized controlled trials, real-world studies, reviews, HTA reports, epidemiologic 
studies, observational studies, patient-reported outcomes studies, registries, case studies, and cost studies
Figure. PRISMA flowchart of the study selection process.
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Table 2. Studies Included in This Review
Author (reference) Year Country Study type Interventions
Pirson et al62 2015 Belgium Case study PICC
Bech et al22 2016 Denmark Retrospective, cohort study PICC, CICC
Christensen et al18 2014 Denmark Prospective study PICC
Christensen et al24 2016 Denmark Retrospective, cohort study PICC
Pedersen et al14 2015 Denmark Retrospective study PICC, PIVC
Lindsay et al63 2007 Europe (unspecified) Single-center randomized study PICC
Betegnie et al37 2014 France Retrospective study PICC
Bouzad et al23 2016 France Retrospective study PICC
Cornillon et al38 2017 France Prospective study PICC
Delarbre et al25 2004 France Retrospective study PICC
Dupont et al12 2015 France Prospective study PICC
Gire et al45 2015 France Prospective single-center study PICC
Grau et al26 2017 France Prospective cohort study PICC
Juntas-Morales et al64 2015 France Prospective study PICC
Juntas-Morales et al48 2017 France Retrospective study PICC
Leroyer et al29 2013 France Prospective study PICC
Moureau et al43 2010 France Prospective study PICC
Toure et al33 2015 France Prospective study PICC, CICC
Valbousquet et al15 2015 France Retrospective study PICC
Vidal et al35 2008 France Prospective study PICC
Konstantinou et al11 2013 Greece Prospective study PICC, CICC
Konstantinou et al65 2015 Greece Case report PICC
Baldinelli et al36 2015 Italy Prospective study PICC
Bellesi et al4 2013 Italy Prospective study PICC
Bonizzoli et al16 2011 Italy Prospective study PICC, CICC
Conte et al47 2015 Italy Prospective single-center study PICC
Cotogni et al5 2013 Italy Prospective, single-center study PICC, CICC
Elli et al13 2017 Italy Prospective study PICC
Falcone et al66 2017 Italy Retrospective, multicenter, case-control study PICC, CICC
Pittiruti et al30 2012 Italy Retrospective study PICC
Salvatori et al44 2016 Italy Retrospective study PICC
Scocca et al46 2008 Italy Prospective study PICC
Sica et al31 2015 Italy Retrospective study PICC
Spaziani et al32 2000 Italy Prospective study PICC
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use and to focus the study on a more homogeneous pop-
ulation)
• Patients with stage 3b chronic kidney disease or greater 
(estimated glomerular filtration rate <45 mL/min)
Data Extraction and Analysis
Data extraction was performed by 1 reviewer and was veri-
fied by a second reviewer. Analysis of extracted data was per-
formed by 3 reviewers, and results were summarized in a pre-
liminary technical report to document all findings.
Results
Study Selection
The PRISMA flowchart of the study selection process is de-
picted in the Figure. The searches of PubMed, EMBASE, and 
Cochrane Database of Systematic Reviews yielded 241, 263, 
and 65 relevant records, respectively, for a total of 569 records 
identified through database searching. Searches of the gray lit-
erature and hand searching of reference lists yielded an addi-
tional 28 records. After exclusion of duplicates, a total of 457 
records were screened by title/abstract for potential eligibili-
ty, and 258 records were excluded based on title and abstract 
screening. A total of 199 full-text materials, including articles, 
reports, and conference abstracts were obtained and scrutinized 
against the selection criteria, of which 56 publications in full 
text were selected for data extraction (Table 2).
A total of 9 countries in Europe are represented by the 56 
studies that were identified. Most studies were conducted in 
France (14 studies), followed by Italy (12 studies) and the 
United Kingdom (10 studies). The remaining studies were con-
ducted in Belgium, Denmark, Greece, Netherlands, Spain, and 
Switzerland, and in one study (conference abstract) the country 
was not specified. The number of patients with a PICC in each 
study varied from 6 to 951. The mean patient age in the studies 
ranged from 18 to 70.2 years.
Table 2. (Continued)
Author (reference) Year Country Study type Interventions
Gerling and Feenstra39 2016 Netherlands Case study PICC
van Boxtel et al34 2008 Netherlands Prospective study PICC
Almirante et al67 2012 Spain Surveillance study PICC, CICC, PIVC
Ayuela Azcarate et al68 2002 Spain Case report PICC
Botella-Carretero et al17 2013 Spain Prospective study PICC, CICC
Hernandez et al27 2011 Spain Cost-utility study PICC
Juve28 2003 Spain Retrospective study PICC, CICC
Navarro Mediavilla et al21 2015 Spain Retrospective study PICC
Rodriguez et al49 2015 Spain Retrospective study PICC
Gardiol et al69 2016 Switzerland Prospective study PICC
Glauser et al40 2016 Switzerland Prospective randomized controlled study PICC
Periard et al10 2008 Switzerland Single-center, randomized controlled study PICC, PIVC
Barr et al70 2012 UK Retrospective cohort study PICC, CICC
El-Ghazali et al71 2015 UK Case report PICC
Griffiths and Philpot 6 2002 UK Prospective study PICC, CICC, PIVC
Johnston et al19 2012 UK Prospective study PICC
Johnston et al72 2013 UK Retrospective study PICC
Johnston et al41 2014 UK Retrospective study PICC
Kumar and Amin42 2004 UK Case report PICC
Le Couteur et al20 2015 UK Retrospective cohort study PICC
Orme et al73 2007 UK Case report PICC
Parcell et al74 2013 UK Retrospective study PICC
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Efficacy Outcomes
Of the 56 studies selected for data extraction, 32 reported 
efficacy outcomes with PICCs alone, and 10 with PICCs versus 
comparators (PIVCs and CICCs). Not all studies reported all 
outcomes. As per the study selection criteria, comparators were 
considered only within the context of studies that also reported 
data on the use of PICCs. No separate searches for comparators 
were performed.
Table 3 provides a summary of the efficacy of PICCs and 
comparators in all studies. For each outcome, data ranges are 
provided, with the number of interventions (n) in brackets. Note 
that the number of interventions does not necessarily correspond 
to the number of studies because studies may include more than 
one intervention of the same type. Case studies were omitted 
from the summary table because single-patient studies would 
skew the range of results for each outcome toward either 0% or 
100%. To complement the data ranges, we have also indicated 
throughout this article whenever a study reported a statistically 
significant difference between PICCs and comparators.
Patient comfort and satisfaction were reported in 2 studies. 
In the randomized study by Periard et al10 comparing PICCs 
with PIVCs for intravenous therapy using an internally validat-
ed questionnaire, 96.8% of patients using PICCs were satisfied 
or very satisfied, compared to 79.3% of patients using PIVCs 
(P < 0.001). In the study by Konstantinou et al,11 mean (SD) 
satisfaction score (scale 1 to 10) with PICCs was 7.78 (3.73) 
versus 6.59 (2.06) with CICCs in patients undergoing elective 
surgery or needing parenteral nutrition and infusion therapy (P 
< 0.001).
Across several studies, pain during catheter insertion was re-
ported in 0% to 18% of patients using PICCs.11–15 In the study 
by Konstantinou et al,11 no significant difference was report-
ed for pain during the procedure between PICCs and CICCs 
(7.7% vs. 12.2%, P = 0.502). In the study by Pedersen et al,14 
8.7% of patients with PICCs experienced pain during insertion, 
compared to 23.4% of patients with PIVC lines. No statistical 
analysis was provided for this comparison.
None of the selected studies reported patient health-related 
quality of life following PICC insertion.
The study by Konstantinou et al11 reported no significant 
difference between PICCs and CICCs (P = 0.18) in the num-
ber of venipunctures required for successful catheter insertion. 
However, fewer venipunctures were required with PICCs ver-
sus PIVCs in the study by Periard at al10 for initial catheter 
insertion (1.16 vs. 2.27, P < 0.01).
The mean number of catheter days ranged between 7.9 and 
176.1 days with PICCs16–21 and was 22.5 to 98.5 days with 
CICCs in 2 studies.16,17 Mean dwell time or mean catheter dura-
tion was defined as the number of days from line insertion until 
line removal. The reported mean catheter dwell time/duration 
ranged from 9.4 to 127 days with PICCs6,10–12,15,16,18,22–35 versus 
4.4 to 7.3 days with PIVCs6,10 and 6.83 to 324.92 days with 
CICCs.6,11,16,22,28,33 In 2 studies, mean catheter dwell time was 
significantly higher for PICCs versus CICCs (P < 0.0001),11,16 
whereas the opposite was true in 2 other studies (P < 0.001).22,33 
In the study by Periard et al10 in patients requiring IV therapy for 
at least 5 days, mean catheter dwell time was significantly high-
er for PICCs compared to PIVCs (9.4 vs. 7.3 days, P = 0.01).
The percentage of patients experiencing placement com-
plications with PICCs ranged from 0 to 7.4%.4,12,15,21,30,31,35–44 
Placement complications were not reported for comparators 
(CICCs and PIVCs).
Safety Outcomes
Among the 56 studies selected for the review, 43 reported 
safety outcomes with PICCs alone, and 13 reported safety out-
comes with PICCs versus comparators (PIVCs and CICCs). 
Table 4 summarizes the minimum and maximum values (rang-
es) of the safety outcomes reported with PICCs and compara-
tors across all studies (number of interventions n in brackets).
The rates of removal due to complications were 3.5% to 48% 
with PICCs4–6,12,14,15,20,23–27,29,32,33,35,37,38,45,46 compared to 67% to 
81.2% with PIVCs6,14 and 26% to 78% with CICCs.5,6,33 In the 
study by Cotogni et al5 in which catheters were used for home 
parenteral nutrition in patients with cancer, the ratio of compli-
cations leading to removal over total complications was signifi-
cantly lower for PICCs versus CICCs (55% vs. 85%, P < 0.05).
Accidental catheter removal was reported in 1% to 8.9% of 
patients with PICCs across studies4,23,26,29,31,35,44 versus 7.8% of 
patients with PIVCs reported in a single study that met the in-
clusion criteria.14 Catheter blockage occurred in 0% to 38% of 
patients with PICCs4,5,12,14,15,17,19,23,26,28,29,32–35,46,47 compared to 0% 
to 16% of patients with CICCs.5,17,28,33 The proportion of pa-
tients reporting catheter migration/dislocation was 0% to 7.7% 
with PICCs5,14,30,33,37 compared to 9.6% to 15% with CICCs.5,33 
In the study by Cotogni et al,5 catheter dislocation was signifi-
Table 3. Summary of Efficacy Outcomes with PICCs and Comparators
Type of 
intervention
Patient 
comfort and 
satisfaction, 
% (n)
Pain during 
catheter 
insertion, % (n)
Number of 
venipunctures 
for catheter 
insertion (n)
Mean catheter 
days (n)
Mean catheter 
dwell time/
duration in days 
(n)
Placement 
complications, 
% (n)
PICC 96.8 (1) 0–18 (5) 1.15*–1.16 (2) 7.9–176.1 (6) 9.4–127 (21) 0–7.4 (16)
PIVC 79.3 (1) 23.4 (1) 2.27 (1) NR 4.4–7.3 (2) NR
CICC NR 12.2 (1) 1 (1) 22.5–98.5 (2) 6.83–324.92 (6) NR
n = number of interventions; NR = not reported.
*Calculated as a weighted average. 
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cantly lower with PICCs compared to CICCs (7% vs.15%, P 
< 0.01).
Rates of catheter fracture/breakage were 0% to 2.1% with 
PICCs across studies4,33,35,37,47 and 1.2% with CICCs in a sin-
gle study.33 The rate of catheter mechanical failure was 5% to 
22.3% with PICCs6,15,18,27,44 and 16% and 11% in PIVCs and 
CICCs, respectively, in a single study.6
The percentage of patients experiencing venous thrombosis 
was 0% to 27.2% with PICCs4,5,10,12,13,15,16,18,20,26,29,31,33,35,37,38,44,48,49 
compared to 3.4% with PIVCs reported in one study10 and 0% 
to 9.6% with CICCs.5,16,17,33 In the study by Bonizzoli et al16 in 
which catheters were used for prolonged IV therapy in patients 
discharged from the intensive care unit, rates of DVT were 
significantly higher for PICCs compared to CICCs (27.2% vs. 
9.6% of patients or 7.7 vs. 4.4 DVTs per 1000 catheter days, 
P = 0.0007). In the study by Toure et al,33 venous thrombosis 
occurred in 7.1% of patients receiving home parenteral nutri-
tion (HPN) via PICCs, whereas no thrombosis was reported for 
patients with CICCs (P = 0.01).
Inflammation (phlebitis, edema) was reported in 0% to 17% 
of patients with PICCs4,6,15,17,18,27,29,33,34,38,46,48 versus 17.5% with 
PIVCs reported in one study6 and 0% to 23% with CICCs.6,17,33 
In the study by Griffiths and Philpot,6 the number of insertion 
sites showing signs of phlebitis was significantly lower in criti-
cally ill patients using PICCs for venous access (17%) compared 
to PIVCs (65%), P < 0.01, but not compared to CICCs (22%).6
Skin reactions were reported in only 2 studies, with cellulitis 
occurring in 3.2% and 0% of patients with PICCs and PIVCs, 
respectively,10 and edema occurring in 4.5% of patients follow-
ing PICC insertion.29
Infections in general (sepsis, local infections, and infec-
tions at insertion site) occurred in 0% to 21% of patients with 
PICCs4–6,11,13–15,18,23,26,27,33,35,37,44,47–49 versus 0% to 14% with 
PIVCs6,10,14 and 0% to 35% with CVCs.5,6,11,33 In the study by 
Toure et al,33 catheter-associated infection (exit site, tunnel, or 
pocket infection) rate was lower in patients receiving HPN by 
PICCs versus CICCs (1.05 vs. 1.87 per 1000 catheter days, P = 
0.01). Rates of central line–associated bloodstream infections 
(CLABSI) with PICCs were 0% to 5.7%,12,15,26,47 and CLABSI 
was not assessed in the studies of PICCs and CICCs. The in-
cidence of catheter-related bloodstream infections (CRBSI) 
with PICCs varied among different studies and ranged from 
0 to 1.63 per 1000 catheter days.4,5,17,22–24,31,34,38 In the study by 
Cotogni et al,5 CRBSI rate was significantly lower with PICCs 
compared to CICCs (0 vs. 0.87 per 1000 catheter days, P < 
0.01), and in the study by Botella-Carretero et al,17 only PICCs, 
but not CICCs, showed lower CRBSI incidence than with im-
planted ports (P = 0.043). However, a higher CRBSI rate and 
a lower time to first CRBSI were reported for PICCs versus 
CICCs in a 6-year follow-up study in HPN patients (1.43 ± 
0.20 vs. 0.95 ± 0.39 per 1000 catheter days, 83.91 ± 93.75 vs. 
297.21 ± 386.91 days, P < 0.001).22
Rates of bleeding complications (hematomas) with PICCs 
ranged from 0% to 8% of patients,4,11,13,23,26,29,30,45 and a rate of 
0% for local hematomas was reported with CICCs in a sin-
gle study with no significant difference compared to PICCs 
(2.56%, P = 0.326).11Ta
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Cost Outcomes
Two studies met the study selection criteria and reported 
cost outcomes for PICCs and their comparators. Konstantinou 
et al11 reported that the mean cost of catheters was higher for 
PICCs versus CICCs (€250.51 vs. €35). However, the study 
did not consider costs of other materials, activities, complica-
tions, or length of hospital stay. The authors note that in their 
experience, CICCs are typically replaced more frequently than 
PICCs, which may have an impact on costs. The study by Peri-
ard et al10 compared costs between PICCs and PIVCs. Overall, 
the cost of materials and activities was evaluated at $690 USD 
(*approx. €504) and $237 USD (€173) per patient for PICC 
and PIVC use, respectively. PICC costs included the catheter 
tray, sterile material for insertion, fluoroscopy, compensation 
of interventional radiologist, and use of the angiography suite. 
In both groups, costs included the material used for catheter 
maintenance, including dressing, valve, fixation device, mate-
rial for saline flush, material for blood sampling, and nurses’ 
salaries during catheter insertion and maintenance. The major 
contributors of the overall cost for PICC insertion were price 
of materials required for insertion ($210 USD [€153]) and an-
giography suite occupancy ($265 USD [€193]). Materials for 
catheter maintenance were $27 USD (€20) per patient in the 
PICC group and $18 USD (€13) in the PIVC group. Nurse time 
was 4.1 hours and 5.5 hours per patient for PICCs and PIVCs, 
respectively, corresponding to a nursing cost of $165 USD 
(€120) and $219 USD (€160), respectively. Although costs as-
sociated with catheter complications or differences in length of 
hospital stay were not factored into this analysis, the authors 
noted that a potential PICC advantage regarding costs may be 
related to an earlier hospital discharge.
Discussion
Overall, the results of this systematic literature review 
demonstrate that PICCs are generally efficacious and safe to 
use in the short- and intermediate term (<6 months) among 
adults in the European setting and in some cases may be pref-
erable to CICCs and PIVCs. However, the risk of DVT, mostly 
asymptomatic, was reported to be higher with PICCs than with 
CICCs in one study, and attention should be paid to factors that 
can reduce this risk.
A previous systematic literature review on the advantages 
and disadvantages of PICCs compared to other central ve-
nous lines including tunneled and nontunneled CICCs and 
venous ports covered literature from any country up to March 
2011.50 The authors noted that scientific evidence supporting 
a thorough comparison of PICCs with traditional central ve-
nous lines was limited. The evidence base has increased in 
the past 6 years, as several relevant studies have since been 
published. The current systematic literature review thus pro-
vides an updated perspective, focusing specifically on the 
use of PICCs in the short/intermediate term in the European 
context.
*The article by Periard et al. only includes costs in USD ($). Conversion to EUR (€) was calculated using the average exchange rate for the year (2007) preceding the date 
of manuscript submission (February 2008), assuming that cost data was collected during 2007. The average EUR/USD exchange rate of 1.3701 for 2007 was obtained 
from the European Central Bank website: https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-graph-usd.en.html
In this updated review, PICCs were associated with higher 
patient satisfaction than were CICCs or PIVCs in studies in 
which catheters were required for more than 1 week but less 
than 1 month. This likely relates to the more discrete nature 
of a PICC versus a CICC and the potential of a single PICC to 
accommodate all infusions and blood sampling during a hos-
pital stay compared to several punctures that may be required 
with PIVCs.10,11 Limited evidence also showed that PICCs 
may be associated with reduced pain compared with CICCs 
and PIVCs.14 However, it should be noted that the studies did 
not report whether local anesthetic was used during insertion, 
which may have an impact on pain, ease of device position-
ing, and patient satisfaction. Similarly, some of the studies used 
nontunneled CICCs, which may have contributed to more dis-
location, infection, and pain, and thus lower patient satisfac-
tion, than if tunneled catheters had been used.
The rates of catheter removal due to complications were con-
sistently reported to be lower for PICCs compared to CICCs 
and PIVCs. PICCs have a low incidence of mechanical com-
plications that would require immediate catheter removal.5 In 
this systematic literature review, catheter migration/dislocation 
was reported to be lower with PICCs compared to CICCs. Such 
complications (dislocation, external rupture) were reported to 
occur less with polyurethane than with silicone PICCs.51
Several factors may influence the risk of PICC-related ve-
nous thrombosis. Catheter size and lumen configuration are 
important factors influencing the risk of thrombotic complica-
tions.52 A prospective study conducted over a period of 3 years 
reported that an increase in the use of single-lumen PICCs and 
the implementation of smaller 5 Fr triple-lumen PICCs were 
associated with a significant decrease in rates of DVT (P < 
0.04).53 Valbousquet Schneider et al15 used smaller size PICCs 
(3 Fr, 20 gauge) and reported no occurrence of thrombosis 
among orthopedic patients on intravenous antibiotic therapy. A 
catheter-to-vein ratio of 45% has been reported to be optimal 
for reducing the risk of venous thromboembolism with PICCs, 
with no difference in risk when using lower ratios.54 The use 
of ultrasound to assist catheter placement is also associated 
with a lower rate of DVT. Dupont et al12 reported that ultra-
sound-guided placement of PICCs was successful in 95.6% 
of procedures, with no insertion complications and only 2% 
of patients experiencing DVT. Cotogni et al5 used ultrasound 
guidance and a sutureless device for catheter insertion and re-
ported no occurrence of DVT with PICCs, compared to 2.8% 
with CICCs. The catheter peripheral insertion site is also a po-
tential contributing factor of thrombosis. Catheter insertion in 
the left arm was associated with increased risk of thrombosis 
compared with the right arm.52 For example, in the study by 
Bonizzoli et al16 in which 144 PICCs were inserted into either 
the left or right basilic vein, a significantly higher rate of DVT 
was associated with the left-side insertion (37.1% vs. 18.3%, 
respectively, P = 0.0347). Based on the anatomy of the upper 
venous system, venous access may be more difficult and there 
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may be an increased potential for obstruction to flow for a cen-
tral venous line located on the left side.55 Some research sug-
gests that the prophylactic use of anticoagulants such as low-
dose warfarin may reduce the risk of catheter-related central 
venous thrombosis. However, there is lack of consensus in the 
clinical guidelines on whether anticoagulant therapy should 
be used for thrombosis prevention, and if so, in which patient 
groups. Anticoagulants are also routinely used to treat venous 
thrombosis after it has occurred.3,56–58
CRBSIs are an important source of hospital-acquired infec-
tions with high clinical and economic burden. Literature- and 
registry-based estimates of CRBSI during intensive care unit 
stays in 4 European countries (France, Germany, Italy, and the 
United Kingdom) indicated 8400 to 14,400 episodes, 1000 to 
1584 deaths, and 15,960 to 201,600 hospital days per year, with 
an overall cost of €35.9 to €163.9 million.59 The current system-
atic literature review uncovered conflicting results regarding 
rates of CRBSI in PICCs versus CICCs in Europe. In another 
systematic review by Maki et al60 that was not restricted to Eu-
ropean studies, PICCs had lower CRBSI rates than short-term 
noncuffed and nonmedicated central venous catheters, but had 
higher rates compared to PIVCs. Further studies are required to 
conclude the incidence of CRBSIs in PICCs versus its compar-
ators in the European setting.
The 2 cost studies meeting the criteria of this review showed 
that catheter costs for PICCs are higher than for CICCs and 
that costs of materials and activities are higher for PICCs than 
for PIVCs. However, a more holistic evaluation of all incurred 
costs, including costs associated with treatment of complica-
tions and duration of hospital stay, should be considered when 
making cost comparisons. In the French study by Periard et 
al,10 although PICC use was associated with higher costs com-
pared to PIVCs, the authors note that a potential advantage 
with PICCs may be related to an earlier hospital discharge, 
which was not taken into account in this study. Another lim-
itation was that the analysis did not include cost of catheter 
complications. In the current review, a comparison of safety 
outcomes in patients with PICCs versus PIVCs showed that pa-
tients with PICCs had fewer complications leading to removal, 
less catheter migration, and a lower inflammation (phlebitis) 
rate. In the study by Konstantinou et al,11 although the cost of 
a single PICC insertion was higher than for a CICC, PICCs 
remained safely in the patient for a longer time (mean duration: 
22.5 days), compared to CICCs (mean duration: 14.56 days), 
which required more frequent replacement. The cost of addi-
tional materials required to ensure maximal sterile conditions 
during CICC placement, as well as additional labor costs (as-
sistants required for the placement procedure) and potentially 
higher risk of complications, were not taken into account and 
could potentially raise the total operational cost of CICCs com-
pared to PICCs.58 Therefore, the total costs per patient are not 
accurately reflected in this study. Further studies are required to 
assess the overall costs associated with PICCs versus compara-
tors over the full treatment duration, with costs of all materials, 
labor, and complications included in the analysis.
This systematic review has some limitations. Firstly, it 
should be noted that there was considerable heterogeneity 
among included studies in terms of study size, study design, 
patient demographics, indication for catheter use, and defini-
tions of measured outcomes. For this reason, a meta-analysis 
was not conducted. Furthermore, to limit the scope of the re-
view and focus on PICCs, only studies that included PICCs 
were considered, including studies of PICCs alone without 
comparators. The data reported for CICCs and PIVCs in this 
review therefore relate only to comparisons with PICCs, de-
spite the availability of other data in excluded studies that do 
not contain PICCs. The scope was further narrowed by ex-
cluding studies in which PICCs were used for chemotherapy, 
which helped to focus on shorter-term duration and to reduce 
the heterogeneity among included studies. However, the find-
ings of this report may therefore not be applicable to the use 
of PICCs in chemotherapy in the short/intermediate term. Al-
though we were able to report on statistical significance from 
individual studies in our review, overall efficacy and safety re-
sults and comparisons between types of catheters across stud-
ies could only be reported as ranges (minimum–maximum), as 
a meta-analysis was not performed. A welcome follow-up to 
our general and broad search would be to conduct a meta-anal-
ysis focusing on specific outcomes within the context of more 
focused search criteria.
Conclusion
In conclusion, this systematic review of the European liter-
ature showed that PICCs offer several advantages compared 
to CICCs and PIVCs in short/intermediate-term use, including 
greater patient satisfaction, fewer complications leading to re-
moval, and less catheter migration/dislocation, despite a mod-
erately higher rate of venous thrombosis.
Relevance to Clinical Practice
The findings of this review may help clinicians better under-
stand the benefits and risks associated with the use of PICCs 
in the short/intermediate term, allowing them to make more 
informed decisions about the appropriateness of their use in 
different clinical scenarios. As outlined in the Infusion Nurse’s 
Society’s standards on VAD selection and placement, the ap-
propriate type of VAD should be selected to accommodate a 
patient’s vascular access needs based on several factors. These 
include prescribed therapy or treatment regimen, anticipated 
duration of therapy, vascular characteristics, patient age, co-
morbidities, history of infusion therapy, preference for VAD 
location, and ability and resources available to care for the de-
vice. The selected VAD should be of the smallest outer diam-
eter with the fewest number of lumens and should be the least 
invasive device needed for the prescribed therapy. Peripheral 
vein preservation should also be considered when planning for 
vascular access. Selection of the most appropriate VAD should 
thus occur as a collaborative process among a multidisciplinary 
team, the patient, and the patient’s caregivers.61
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